Conversations with the LRG: GIST Mentors
GIST Mentors Santy DiSabatino, Marlene Nei and Rob Taylor will discuss the role of the GIST Mentor and how a Mentor can assist you on your GIST journey.
Blueprint Medicines Announces Publication in The Lancet Oncology
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Help Us Celebrate GIST Awareness Day with #GISTHope
For GIST Awareness Day, to celebrate our theme of #GISTHope, we’re asking you to spread the word about GIST on social media and out in the world.
Heroes on the Frontline: Dr. Jonathan Trent
The LRG was fortunate to get a few minutes with GIST specialist, Jonathan Trent, MD, Sylvester Comprehensive Cancer Center, who shared his experience with his patients over the past few months during the coronavirus pandemic.
Heroes on the Frontline: Eric Lindberg
Eric Lindberg, diagnosed with GIST in 2017, works as an emergency room nurse and has been on the frontlines throughout the COVID-19 pandemic.
Heroes on the Frontline: Dr. Matthew Lurin
Q&A with a LRG Major Donor & Fundraiser
Long-Term Survivor Stories – Chuck Korte & Dina Wiley
For GIST patients, long term survival is the ultimate goal. A number of factors may influence long term survival – some of these are demographic and clinical, like mutational subtype and genetic factors. However, there are a number of others that are perhaps more subtle, such as lifestyle, attitude, and access to treatment, experts, and advice.
Making the Right Decisions in Tough Times
Amelia Yeo, LRG Country Liaison for Singapore and GIST caregiver, describes how she and her husband are doing during this global health pandemic.
You Are the Hope
Hope is an important resource during difficulty times. Mary Garland, Director of Communications for the LRG, shares her observations on hope.
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.